Claudia Scholl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Claudia Scholl has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Katrin Faber
Department of Internal Medicine III, Ulm University, Ulm, Germany
3 shared publicationsHartmut Döhner
2 shared publications- Stefan Fröhling
Department of Internal Medicine III, 2Department of Urology, and 3Institute for Neural Information Processing, Ulm University, 89081 Ulm, Germany
2 shared publications - Stefan Fröhling
National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany
2 shared publications Stephen M. Sykes
Immune Cell Development and Host Defense Program, Fox Chase Cancer Center, Philadelphia, PA; and
2 shared publications- Ali Nowrouzi
Department of Translational Oncology, German Cancer Research Center, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany
1 shared publication
Latest Publications
- Open Access
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S54-S55
134. Gene Editing Approaches for Investigating Therapy-Resistance in Soft-Tissue Sarcoma
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S54-S55
Open Access134. Gene Editing Approaches for Investigating Therapy-Resistance in Soft-Tissue Sarcoma
- Open Access
- 3 July 2014
- Published by American Society of Hematology in Blood
- Vol. 124 (1) , 13-23
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
Key Points: CDK6 is a critical effector of MLL fusions in myeloid leukemogenesis. Genetic and pharmacologic inhibition of CDK6 overcome the differentiation block associated with MLL-rearranged AML.
- 3 July 2014
- Published by American Society of Hematology in Blood
- Vol. 124 (1) , 13-23
Open AccessRequirement for CDK6 in MLL-rearranged acute myeloid leukemia
Key Points: CDK6 is a critical effector of MLL fusions in myeloid leukemogenesis. Genetic and pharmacologic inhibition of CDK6 overcome the differentiation block associated with MLL-rearranged AML.
- 12 June 2013
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 138 (25/26) , 1369-1372
Nutzung funktioneller Abhängigkeiten in Tumorzellen zur Entwicklung zielgerichteter Therapien
- 12 June 2013
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 138 (25/26) , 1369-1372
Nutzung funktioneller Abhängigkeiten in Tumorzellen zur Entwicklung zielgerichteter Therapien
- Open Access
- 3 December 2012
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 123 (1) , 299-314
CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling
Aberrant expression of the homeodomain transcription factor CDX2 occurs in most cases of acute myeloid leukemia (AML) and promotes leukemogenesis, making CDX2, in principle, an attractive therapeutic target. Conversely, CDX2 acts as a tumor suppressor in colonic epithelium. The effectors mediating the leukemogenic activity of CDX2 and the mechanism underlying its context-dependent properties are poorly characterized, and strategies for interfering with CDX2 function in AML remain elusive. We report data implicating repression of the transcription factor KLF4 as important for the oncogenic activity of CDX2, and demonstrate that CDX2 differentially regulates KLF4 in AML versus colon cancer cells through a mechanism that involves tissue-specific patterns of promoter binding and epigenetic modifications. Furthermore, we identified deregulation of the PPARγ signaling pathway as a feature of CDX2-associated AML and observed that PPARγ agonists derepressed KLF4 and were preferentially toxic to CDX2+ leukemic cells. These data delineate transcriptional programs associated with CDX2 expression in hematopoietic cells, provide insight into the antagonistic duality of CDX2 function in AML versus colon cancer, and suggest reactivation of KLF4 expression, through modulation of PPARγ signaling, as a therapeutic modality in a large proportion of AML patients.
- 3 December 2012
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 123 (1) , 299-314
Open AccessCDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling
Aberrant expression of the homeodomain transcription factor CDX2 occurs in most cases of acute myeloid leukemia (AML) and promotes leukemogenesis, making CDX2, in principle, an attractive therapeutic target. Conversely, CDX2 acts as a tumor suppressor in colonic epithelium. The effectors mediating the leukemogenic activity of CDX2 and the mechanism underlying its context-dependent properties are poorly characterized, and strategies for interfering with CDX2 function in AML remain elusive. We report data implicating repression of the transcription factor KLF4 as important for the oncogenic activity of CDX2, and demonstrate that CDX2 differentially regulates KLF4 in AML versus colon cancer cells through a mechanism that involves tissue-specific patterns of promoter binding and epigenetic modifications. Furthermore, we identified deregulation of the PPARγ signaling pathway as a feature of CDX2-associated AML and observed that PPARγ agonists derepressed KLF4 and were preferentially toxic to CDX2+ leukemic cells. These data delineate transcriptional programs associated with CDX2 expression in hematopoietic cells, provide insight into the antagonistic duality of CDX2 function in AML versus colon cancer, and suggest reactivation of KLF4 expression, through modulation of PPARγ signaling, as a therapeutic modality in a large proportion of AML patients.
- Open Access
- 27 March 2012
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 209 (4) , 697-711
Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33
Previous efforts to develop drugs that directly inhibit the activity of mutant KRAS, the most commonly mutated human oncogene, have not been successful. Cancer cells driven by mutant KRAS require expression of the serine/threonine kinase STK33 for their viability and proliferation, identifying STK33 as a context-dependent therapeutic target. However, specific strategies for interfering with the critical functions of STK33 are not yet available. Here, using a mass spectrometry-based screen for STK33 protein interaction partners, we report that the HSP90/CDC37 chaperone complex binds to and stabilizes STK33 in human cancer cells. Pharmacologic inhibition of HSP90, using structurally divergent small molecules currently in clinical development, induced proteasome-mediated degradation of STK33 in human cancer cells of various tissue origin in vitro and in vivo, and triggered apoptosis preferentially in KRAS mutant cells in an STK33-dependent manner. Furthermore, HSP90 inhibitor treatment impaired sphere formation and viability of primary human colon tumor-initiating cells harboring mutant KRAS. These findings provide mechanistic insight into the activity of HSP90 inhibitors in KRAS mutant cancer cells, indicate that the enhanced requirement for STK33 can be exploited to target mutant KRAS-driven tumors, and identify STK33 depletion through HSP90 inhibition as a biomarker-guided therapeutic strategy with immediate translational potential.
- 27 March 2012
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 209 (4) , 697-711
Open AccessTargeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33
Previous efforts to develop drugs that directly inhibit the activity of mutant KRAS, the most commonly mutated human oncogene, have not been successful. Cancer cells driven by mutant KRAS require expression of the serine/threonine kinase STK33 for their viability and proliferation, identifying STK33 as a context-dependent therapeutic target. However, specific strategies for interfering with the critical functions of STK33 are not yet available. Here, using a mass spectrometry-based screen for STK33 protein interaction partners, we report that the HSP90/CDC37 chaperone complex binds to and stabilizes STK33 in human cancer cells. Pharmacologic inhibition of HSP90, using structurally divergent small molecules currently in clinical development, induced proteasome-mediated degradation of STK33 in human cancer cells of various tissue origin in vitro and in vivo, and triggered apoptosis preferentially in KRAS mutant cells in an STK33-dependent manner. Furthermore, HSP90 inhibitor treatment impaired sphere formation and viability of primary human colon tumor-initiating cells harboring mutant KRAS. These findings provide mechanistic insight into the activity of HSP90 inhibitors in KRAS mutant cancer cells, indicate that the enhanced requirement for STK33 can be exploited to target mutant KRAS-driven tumors, and identify STK33 depletion through HSP90 inhibition as a biomarker-guided therapeutic strategy with immediate translational potential.